Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report by The Business Research Company covers G-CSF (granulocyte colony stimulating factors) market drivers and restraints, G-CSF (granulocyte colony stimulating factors) market size, major players, and the impact of COVID-19 on the G-CSF (granulocyte colony stimulating factors) market.
The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy.
The increasing prevalence of cancer is a key factor driving the growth of the granulocyte colony stimulating factors market. The global G-CSF (granulocyte colony stimulating factors) market is expected to grow from $6.93 billion in 2020 to $7.37 billion in 2021 at a compound annual growth rate (CAGR) of 6.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The G-CSF market is expected to reach $9.17 billion in 2025 at a CAGR of 6%.
Request A Sample For The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp
Some G-CSF (granulocyte colony stimulating factors) market trends include mergers and acquisitions. In June 2019, Pfizer Inc., a US-based pharmaceutical corporation, acquired Array BioPharma Inc. for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. This acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory, particularly in the long term. Array BioPharma Inc, a US-based company, is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
Global G-CSF (granulocyte colony stimulating factors) market segments include:
1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex).
2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Others.
3) By Product: Tablet, Capsule, Others.
By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2021: COVID-19 Growth And Change To 2030 At:
The G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides G-CSF (granulocyte colony stimulating factors) market overviews, analyzes and forecasts market size, share, G-CSF (granulocyte colony stimulating factors) market players, G-CSF (granulocyte colony stimulating factors) market segments and geographies, market’s leading competitors’ revenues, profiles and market shares.
The G-CSF (granulocyte colony stimulating factors) market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Where To Learn More:
Read G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2021: COVID-19 Growth And Change To 2030 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country, Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries.
Market Players Covered: BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy’s Laboratories, Celltrion Inc., Emcure Pharmaceuticals.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)
Other Information And Analyses: SWOT analysis, customer information, market product/service analysis – product examples, trends and opportunities, drivers and restraints, key mergers and acquisitions, suggested trend based strategies, impact of COVID-19 on the market, future outlook and potential analysis, key metrics covered: number of enterprises, number of employees, global market in 2021 – countries offering most new opportunities, conclusions and recommendations by expert analysts.
Sourcing And Referencing: Data and analysis throughout the report are sourced using end notes.
Strategies For Participants In The G-CSF (Granulocyte Colony Stimulating Factors) Industry: The report explains a number of strategies for companies in the market, based on industry trends and company analysis.
Opportunities For Companies In The G-CSF (Granulocyte Colony Stimulating Factors) Sector: The report reveals where the global industry will put on most $ sales up to 2023.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Here is a list of reports from The Business Research Company similar to the G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2021: